US Stock Futures Flat; All Eyes On FOMC Decision

Loading...
Loading...
Pre-open movers
US stock futures traded mostly flat in early pre-market trade. The consumer price index for August and current-account data for the second quarter will be released at 8:30 a.m. ET. The NAHB housing market index for September will be released at 10:00 a.m. ET. The Federal Open Market Committee will announce its policy decision at 2:00 p.m. ET, while the Fed Chairwoman Janet Yellen will hold a press conference at 2:30 p.m. ET. Futures for the Dow Jones Industrial Average gained 3 points to 17,057.00, while the Standard & Poor's 500 index futures rose 0.30 points to 1,991.80. Futures for the Nasdaq 100 index dropped 2.75 points to 4,055.50.
A Peek Into Global Markets
European markets were higher today, with the Spanish Ibex Index rising 0.88%, STOXX Europe 600 Index gaining 0.59%. German DAX 30 index rose 0.47%, French CAC 40 Index surged 0.71% and London's FTSE 100 Index gained 0.14%. The UK unemployment rate declined to 6.2% in the three months to July, versus 6.4% in the three months to June. In Asian markets, Japan's Nikkei Stock Average tumbled 0.14%, Hong Kong's Hang Seng Index jumped 1%, China's Shanghai Composite Index gained 0.49% and India's BSE Sensex surged 0.52%.
Broker Recommendation
Analysts at Piper Jaffray downgraded FactSet Research Systems
FDS
from Overweight to Neutral. The target price for FactSet Research has been lowered from $134 to $130. FactSet's shares closed at $126.76 yesterday.
Breaking news
  • Alcoa AA today announced the pricing of its public offering of 25,000,000 of its depositary shares at $50 per Depositary Share. To read the full news, click here.
  • Achaogen AKAO announced today that the first patient has been enrolled in a Phase 3 clinical trial of plazomicin to treat infections caused by carbapenem-resistant Enterobacteriaceae (CRE). To read the full news, click here.
  • Shares of Lennar LEN surged more than 4% in pre-market trading after the company reported better-than-expected fiscal third-quarter earnings. To read the full news, click here.
  • Concert Pharmaceuticals CNCE today announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with Celgene CELG.To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsConsumer DiscretionaryFederal Open Market CommitteeHomebuildingPiper JaffrayUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...